loading page

Caffeine and Bronchopulmonary dysplasia :Clinical Benefits and Its Mechanisms
  • +1
  • Yuan Yuan,
  • Yang yang,
  • Xiaoping Lei,
Yuan Yuan
The Affiliated Hospital of Southwest Medical University
Author Profile
Yang yang
The Affiliated Hospital of Southwest Medical University
Author Profile
Xiaoping Lei
The Affiliated Hospital of Southwest Medical University
Author Profile
Southwest Medical University Affiliated Hospital
Author Profile


Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease caused by a combination of prenatal and postnatal factors that leads to the disruption of lung development and abnormal repair, this is a condition that is commonly seen in premature infants. With the improvement of treatment technology, the survival rate of very early preterm infants has increased significantly compared with before, and the incidence of severe BPD has decreased, however, the prevalence of BPD has not decreased. The overall prevalence of BPD is 45%.The prevention of prematurity, the systematic use of non-aggressive ventilator measures, the avoidance of supra-physiological oxygen exposure, and the administration of diuretics, caffeine and vitamin A have all been shown to lead to a significant reduction in the risk of BPD development. A growing number of clinical studies have shown that caffeine not only prevents apnea, but also reduces the incidence of BPD. We review the clinical value of caffeine in the treatment of BPD and its potential mechanisms of action, include anti-inflammatory, antioxidant, anti-fibrotic, anti-apoptotic pathways, and the regulation of angiogenesis. Our aim was to provide a new theoretical basis for the clinical treatment of BPD.

Peer review status:IN REVISION

25 Nov 2021Submitted to Pediatric Pulmonology
27 Nov 2021Assigned to Editor
27 Nov 2021Submission Checks Completed
02 Dec 2021Reviewer(s) Assigned
23 Dec 2021Review(s) Completed, Editorial Evaluation Pending
27 Dec 2021Editorial Decision: Revise Major